{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["antiemetic guideline recommendations", "antiemetic treatment", "carboplatin", "chemotherapy-induced nausea and vomiting (CINV)", "moderate emetic risk regimen"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34916721", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "07"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": ["10.18999/nagjms.83.4.773"], "Journal": {"ISSN": "2186-3326", "JournalIssue": {"Volume": "83", "Issue": "4", "PubDate": {"Year": "2021", "Month": "Nov"}}, "Title": "Nagoya journal of medical science", "ISOAbbreviation": "Nagoya J Med Sci"}, "ArticleTitle": "Is area under the curve the best parameter for carboplatin induced emetic risk stratification?", "Pagination": {"StartPage": "773", "EndPage": "785", "MedlinePgn": "773-785"}, "Abstract": {"AbstractText": ["Carboplatin (CBDCA)-induced emetic risk is currently classified on the basis of CBDCA-area under the curve (CBDCA-AUC). We investigated the utility of three CBDCA dosage parameters for predicting emesis by CBDCA. Patients with thoracic cancer treated with CBDCA were included. The endpoints were complete response (CR) and total control (TC). CR was defined as no vomiting and no use of rescue medication during the overall assessment period, whereas TC was defined as no vomiting, nausea, nor use of rescue medication during the overall assessment period. The parameters of CBDCA were defined as follows: (1) CBDCA-AUC; (2) CBDCA/body surface area (BSA): the administered dose of CBDCA per body surface area (mg/m<sup>2</sup>); and (3) total CBDCA/body: the total administered dose of CBDCA (mg). Eighty-five patients were evaluated. The median CBDCA/BSA but not CBDCA-AUC was higher in patients with non-CR compared to those with CR. Receiver operating characteristic curve analysis revealed that the AUC of CBDCA/BSA for predicting non-CR was higher than that of CBDCA-AUC. CBDCA/BSA shows greater potential for predicting CBDCA-induced emetic risk compared with CBDCA-AUC, which is the parameter in current antiemetic guidelines."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Ozone", "ForeName": "Sachiko", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Nagoya University Hospital, Nagoya, Japan."}], "LastName": "Ichikawa", "ForeName": "Kazuya", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Morise", "ForeName": "Masahiro", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Matsui", "ForeName": "Akira", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan."}], "LastName": "Kinoshita", "ForeName": "Fumie", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Matsuzawa", "ForeName": "Reiko", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Koyama", "ForeName": "Junji", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Tanaka", "ForeName": "Ichidai", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan."}], "LastName": "Hashimoto", "ForeName": "Naozumi", "Initials": "N"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Japan", "MedlineTA": "Nagoya J Med Sci", "NlmUniqueID": "0412011", "ISSNLinking": "0027-7622"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiemetics"}, {"RegistryNumber": "0", "NameOfSubstance": "Emetics"}, {"RegistryNumber": "BG3F62OND5", "NameOfSubstance": "Carboplatin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Aged, 80 and over"}, {"QualifierName": [], "DescriptorName": "Antiemetics"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Carboplatin"}, {"QualifierName": [], "DescriptorName": "Emetics"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Nausea"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}, {"QualifierName": ["methods"], "DescriptorName": "Risk Assessment"}], "CoiStatement": "All authors declare no conflict interest in regard to the current study."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u2013125. doi:10.1056/NEJMoa1713137.", "ArticleIdList": ["10.1056/NEJMoa1713137", "29151359"]}, {"Citation": "Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u2013838. doi:10.1056/NEJMoa1704795.", "ArticleIdList": ["10.1056/NEJMoa1704795", "28586279"]}, {"Citation": "Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17(10):1426\u20131434. doi:10.1016/S1470-2045(16)30269-8.", "ArticleIdList": ["10.1016/S1470-2045(16)30269-8", "27575024"]}, {"Citation": "Ho GY, Woodward N and Coward JI. Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016;102:37\u201346. doi:10.1016/j.critrevonc.2016.03.014.", "ArticleIdList": ["10.1016/j.critrevonc.2016.03.014", "27105947"]}, {"Citation": "Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87\u201395. doi:10.1007/s00520-018-4464-y.", "ArticleIdList": ["10.1007/s00520-018-4464-y", "30284039"]}, {"Citation": "Einhorn LH, Rapoport B, Navari RM, Herrstedt J and Brames MJ: 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25(1):303\u2013308. doi:10.1007/s00520-016-3449-y.", "ArticleIdList": ["10.1007/s00520-016-3449-y", "27815710"]}, {"Citation": "Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American society of clinical oncology focused guideline update. J Clin Oncol. 2016;34(4):381\u2013386. doi:10.1200/JCO.2015.64.3635.", "ArticleIdList": ["10.1200/JCO.2015.64.3635", "26527784"]}, {"Citation": "Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u20133261. doi:10.1200/JCO.2017.74.4789.", "ArticleIdList": ["10.1200/JCO.2017.74.4789", "28759346"]}, {"Citation": "Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520\u2013528. doi:10.1200/JCO.1992.10.4.520.", "ArticleIdList": ["10.1200/JCO.1992.10.4.520", "1548516"]}, {"Citation": "Zhu Y, Xing P, Wang S, et al. Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma. Thorac Cancer. 2018;9(3):400\u2013407. doi:10.1111/1759-7714.12594.", "ArticleIdList": ["10.1111/1759-7714.12594", "PMC5832477", "29377581"]}, {"Citation": "Fujii H, Iihara H, Kajikawa N, et al. Control of nausea based on risk analysis in patients with esophageal and gastric cancer who received cisplatin-based chemotherapy. Anticancer Res. 2017;37(12):6831\u20136837. doi:10.21873/anticanres.12144.", "ArticleIdList": ["10.21873/anticanres.12144", "29187462"]}, {"Citation": "Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase ii trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010;5(12):1963\u20131969. doi:10.1097/JTO.0b013e3181fd42eb.", "ArticleIdList": ["10.1097/JTO.0b013e3181fd42eb", "21102260"]}, {"Citation": "Hayashi T, Shimokawa M, Matsuo K, et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis. BMC Cancer. 2021;21(1):74. doi:10.1186/s12885-021-07802-y.", "ArticleIdList": ["10.1186/s12885-021-07802-y", "PMC7811213", "33451299"]}, {"Citation": "Ando Y, Minami H, Saka H, Ando M, Sakai S and Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert\u2019s formula for carboplatin dosing. Br J Cancer. 1997;76(8):1067\u20131071. doi:10.1038/bjc.1997.509.", "ArticleIdList": ["10.1038/bjc.1997.509", "PMC2228094", "9376268"]}, {"Citation": "Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer. 2010;18(4):423\u2013431. doi:10.1007/s00520-009-0680-9.", "ArticleIdList": ["10.1007/s00520-009-0680-9", "19568773"]}, {"Citation": "Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: A multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21(3):491\u2013497. doi:10.1007/s10147-015-0928-y.", "ArticleIdList": ["10.1007/s10147-015-0928-y", "26662632"]}, {"Citation": "Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109(4):859\u2013865. doi:10.1038/bjc.2013.400.", "ArticleIdList": ["10.1038/bjc.2013.400", "PMC3749572", "23860530"]}, {"Citation": "Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84(3):259\u2013264. doi:10.1016/j.lungcan.2014.03.017.", "ArticleIdList": ["10.1016/j.lungcan.2014.03.017", "24746177"]}, {"Citation": "Jordan K, Blattermann L, Hinke A, Muller-Tidow C and Jahn F. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? -a systematic review and meta-analysis. Support Care Cancer. 2018;26(1):21\u201332. doi:10.1007/s00520-017-3857-7.", "ArticleIdList": ["10.1007/s00520-017-3857-7", "28861627"]}, {"Citation": "Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315\u20131316. doi:10.1097/JTO.0b013e3181ec173d.", "ArticleIdList": ["10.1097/JTO.0b013e3181ec173d", "20736804"]}, {"Citation": "Oguri T, Shimokata T, Ito I, et al. Extension of the calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol. 2015;76(1):53\u201359. doi:10.1007/s00280-015-2769-9.", "ArticleIdList": ["10.1007/s00280-015-2769-9", "25957958"]}, {"Citation": "Rybak MJ: Pharmacodynamics: Relation to antimicrobial resistance. Am J Infect Control. 2006;34(5 Suppl 1):S38\u201345;discussion S64\u201373. doi:10.1016/j.ajic.2006.05.227.", "ArticleIdList": ["10.1016/j.ajic.2006.05.227", "16813981"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "11", "Day": "12"}, {"Year": "2021", "Month": "3", "Day": "22"}, {"Year": "2021", "Month": "12", "Day": "17", "Hour": "6", "Minute": "49"}, {"Year": "2021", "Month": "12", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34916721", "PMC8648517", "10.18999/nagjms.83.4.773"]}}], "PubmedBookArticle": []}